Eosinophilic granulomatosis with polyangiitis, formerly known as Churg-Strauss syndrome, represents a rare necrotizing vasculitis that damages small-to-medium vessels. Clinicians frequently encounter significant EGPA diagnostic delay, primarily because early prodromal features masquerade as common allergic airway conditions before systemic vasculitis emerges.

The Burden and Impact of EGPA Diagnostic Delay

Diagnostic latency poses substantial hazards across systemic vasculitides, but it proves especially challenging in eosinophilic disorders. In a recent retrospective study by Mulkareddy and colleagues, researchers evaluated adult patients to quantify diagnostic latency and identify associated clinical factors. Strikingly, the average time to diagnosis from symptom onset was 4.82 years. This extended latency exposes patients to protracted systemic inflammation, progressive organ damage, and substantial morbidity before anyone implements appropriate immunosuppressive therapy.

During these prolonged years, patients typically rotate through multiple outpatient clinics seeking symptom relief. Because asthma and chronic rhinosinusitis are common respiratory presentations, physicians frequently treat these manifestations in isolation. Consequently, underlying vasculitic progression often remains undetected beneath recurrent bronchospasm and nasal congestion. When practitioners miss early multi-organ signals, patients face an elevated danger of irreversible tissue injury, such as peripheral neuropathy or cardiac compromise. Therefore, recognizing that diagnostic latency averages nearly five years emphasizes why clinicians must maintain heightened clinical vigilance during initial assessments.

Prevalent Clinical Phenotypes: Asthma, Rhinosinusitis, and Pulmonary Infiltrates

The clinical course of EGPA traditionally develops across distinct phases, beginning with prodromal allergic airway disease. In the study cohort, bronchial asthma and chronic rhinosinusitis occurred in 80.5% of patients, underscoring their prominence as cardinal diagnostic clues. Furthermore, nasal polyposis was identified in over half of the individuals. Remarkably, an overwhelming majority of patients suffering from chronic rhinosinusitis underwent endoscopic sinus surgery before doctors established the definitive diagnosis of systemic vasculitis.

Chest imaging also demonstrated high diagnostic utility, revealing transient pulmonary infiltrates or lung nodules in 77.8% of individuals. However, because these clinical findings frequently occur in benign atopic conditions, physicians often evaluate them in isolated specialty silos. For instance, an otolaryngologist might excise recurrent polyps without evaluating peripheral eosinophil counts. Similarly, a pulmonologist might escalate bronchodilators without screening for systemic vasculitic involvement. Thus, encountering severe sinusitis requiring surgery alongside late-onset asthma and transient pulmonary lesions must immediately trigger a comprehensive vasculitis evaluation.

Clinical Predictors Prolonging the Diagnostic Interval

Understanding which specific factors prolong the diagnostic timeline allows physicians to identify vulnerable patient subsets earlier. The investigation revealed that a diagnostic delay exceeding three years was significantly associated with female sex, demonstrating an odds ratio of 6.7. This notable disparity suggests that atypical presentations, referral delays, or diagnostic biases may disproportionately affect women presenting with complex inflammatory syndromes. Furthermore, prior treatment with targeted biologics exhibited a strong association with extended delays, showing an odds ratio of 7.1.

Although targeted biologic therapies effectively suppress eosinophilic airway inflammation, they frequently obscure deeper systemic disease activity. When physicians prescribe monoclonal antibodies for refractory asthma, these agents blunt circulating eosinophil counts without arresting underlying necrotizing vasculitis. Consequently, patients often experience temporary symptomatic improvement in respiratory parameters, which inadvertently delays thorough vasculitis investigations. Therefore, clinicians must maintain high suspicion when patients show incomplete therapeutic responses or manifest unexplained constitutional symptoms despite modern biologic therapy.

Features Accelerating Diagnosis: ANCA Positivity and Renal Involvement

In contrast to variables that prolong diagnostic delays, distinct serological and organ-specific features significantly accelerate disease recognition. The investigators noted that elevated antineutrophil cytoplasmic antibodies, specifically cytoplasmic ANCA patterns, correlated with markedly lower odds of diagnostic delay, yielding an odds ratio of 0.11. Because clinicians widely understand positive ANCA serology as a definitive hallmark of systemic vasculitis, abnormal serological testing reliably prompts immediate rheumatology referrals and intensive investigations.

Similarly, the presence of renal involvement significantly reduced diagnostic latency. When patients develop proteinuria, active urinary sediments, or rising serum creatinine, medical teams rapidly suspect glomerulonephritis and pursue renal biopsy. However, renal manifestations occur in only a minority of EGPA cases, as the disease predominantly involves respiratory tissues and peripheral nerves. Thus, clinicians cannot rely exclusively on renal involvement or seropositivity to raise suspicion. Instead, physicians must aggressively evaluate patients presenting with persistent eosinophilia and unexplained multisystem complaints, even when serology remains completely negative.

Multidisciplinary Pathways and Proactive Clinical Strategies

Eliminating diagnostic bottlenecks requires a structured multidisciplinary care pathway involving pulmonology, rheumatology, otolaryngology, and general practice. Primary care physicians evaluating severe, adult-onset asthma must routinely measure absolute eosinophil counts and review longitudinal lab trends. Furthermore, when patients with refractory chronic rhinosinusitis require repeated surgical interventions, otolaryngologists should systematically screen for extra-sinus manifestations. Unexplained peripheral neuropathy, cutaneous purpura, or constitutional symptoms should immediately prompt comprehensive vasculitis testing.

Standardized diagnostic protocols should incorporate comprehensive blood counts, complete metabolic panels, urinalysis with microscopy, and ANCA serologies. Additionally, clinicians should obtain high-resolution chest computed tomography and electromyography whenever neuromuscular symptoms arise. Histopathological confirmation provides definitive clarity; therefore, clinicians should biopsy affected tissues, including skin or sural nerves, prior to initiating aggressive systemic immunosuppression. By combining routine biomarker tracking with cross-specialty communication, healthcare teams can dismantle clinical silos. This proactive strategy ensures timely diagnosis, facilitating early remission-induction therapy and preventing permanent end-organ damage.

What primary clinical clues should raise suspicion for EGPA in asthma patients?

Clinicians should suspect EGPA when an adult patient presents with difficult-to-control asthma accompanied by marked peripheral eosinophilia and severe chronic rhinosinusitis. Furthermore, the presence of migratory pulmonary infiltrates, recurrent nasal polyps requiring surgical interventions, and unexplained systemic symptoms such as fever or weight loss warrants immediate investigation. Developing peripheral neuropathies, such as mononeuritis multiplex or asymmetric paresthesias, strongly suggests systemic vasculitic transformation requiring prompt multidisciplinary assessment and comprehensive serological testing.

Why does prior biologic treatment often contribute to delayed diagnosis in EGPA?

Biologic therapies targeting eosinophilic pathways, such as anti-interleukin-5 agents, effectively suppress peripheral eosinophil counts and improve upper and lower respiratory symptoms. Consequently, this symptomatic relief often masks ongoing necrotizing vasculitis and quiet systemic progression. Clinicians may attribute clinical improvements to well-controlled allergic asthma, inadvertently delaying comprehensive diagnostic workups. Therefore, physicians must maintain vigilance and perform regular multi-organ evaluations whenever patients on biologics present with atypical systemic symptoms or unexpected organ dysfunction.

How does ANCA positivity influence the clinical course and recognition of EGPA?

Only forty to fifty percent of patients with EGPA test positive for antineutrophil cytoplasmic antibodies, typically targeting myeloperoxidase. However, ANCA positivity significantly accelerates clinical recognition because positive serology prompts immediate rheumatologic evaluation. ANCA-positive individuals more frequently exhibit overt glomerulonephritis, alveolar hemorrhage, and cutaneous vasculitis. Conversely, ANCA-negative patients predominantly display tissue eosinophilia, marked myocardial involvement, and severe airway obstruction. Thus, negative ANCA serology never rules out EGPA when characteristic clinical features and tissue eosinophilia persist.

Disclaimer: This content is for informational and educational purposes only... Refer to the latest local and national guidelines for clinical practice.

References

Mulkareddy V et al. Diagnostic Delay in Eosinophilic Granulomatosis With Polyangiitis: Clinical Predictors and Implications for Earlier Recognition. Allergy. 2026 Sep 27. doi: 10.1111/all.70528. PMID: 42801333.

Wechsler ME, Akuthota P, Jayne D, et al. Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 2017;376(20):1921-1932.

Cottin V, Bel E, Bottero P, et al. Respiratory manifestations of eosinophilic granulomatosis with polyangiitis (Churg-Strauss). Eur Respir J. 2016;48(5):1429-1441.